Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA PSE concerns

This article was originally published in The Tan Sheet

Executive Summary

In light of the recent passage of the Combat Methamphetamine Act, "the one thing that we have some concerns about is that industry is just going to sort of blow [pseudoephedrine] away and not pay any attention or have any interest in marketing it," according to Charles Ganley, MD, director of FDA's Office of Nonprescription Products. "I think that would be a downside for the consumer," he said while speaking at the Consumer Healthcare Products Association's recent Regulatory & Scientific Conference. "I know there's been a shift to try to substitute phenylephrine and have that product available OTC, but I think we ought to see how this can work out on this behind-the-counter type status and see if that is a process that could work. So I would hope you would not dismiss pseudoephedrine in the future," Ganley said. The legislation was passed in March as an amendment to the Patriot Act Reauthorization. The bill places sales limits on products containing the ingredient, and will require behind-the-counter sale of all pseudoephedrine products in September...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts